1. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur
J Vasc Endovasc Surg 2009; 38:6670. ().
2. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent
claudication in subjects with peripheral arterial disease. A meta-analysis of randomized
controlled trials. Arch Intern Med 1991;151:17691776. ().
Oparil S., Chrysant S. G., Melino M., Lee J., Karki S., Heyrman R. Long- term efficacy of a combination of amlodipine and olmesartan medoxomil +/ hydrochlorothiazide in pa-tients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial // J Hum Hypertens. 2010; 24 (12): 831838.
Brown M. J., McInnes G. T., Papst C. C., Zhang J., MacDonald T. M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial // Lancet. 2011; 377 (9762): 312320. Epub Jan 12, 2011. ()
1. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical
management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh
report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment
of High Blood Pressure. Hypertension 2003; 42:12061252.
.
, , ,
, , .
500 100 , 350 , , , 300 , 100 50 .
;
;
, - ;
, ;
( );
( );
;
, ;
- - ;
15 ;
;
;
;
;
;
.
- , , ( );
- - - , - ;
- , ;
- ( );
- .
300-325 ;
:
, , ();
;
( );
.
.
, ( ), (). , .
1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the
primary and secondary prevention of vascular disease: collaborative meta-analysis of
individual participant data from randomised trials. Lancet 2009; 373:18491860. ()
2. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is
beneficial in hypertensive patients with chronic kidney disease: a posthoc()
1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al., JUPITER
Study Group. Rosuvastatin to prevent vascular events in men and women with elevated
C-reactive protein. N Engl J Med 2008; 359:21952207. ().
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and
safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000
participants in 26 randomised trials. Lancet 2010; 376:16701681.()